tadalafil has been researched along with Diabetes Mellitus, Type 2 in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, Y; Inamura, S; Ito, H; Kobayashi, H; Nagase, K; Taga, M; Yokoyama, O; Zha, X | 1 |
| Badagliacca, R; Barbagallo, F; Barbano, B; Caboni, P; Campolo, F; Carbone, I; Catalano, C; Ciolina, F; Defeudis, G; Feola, T; Filardi, T; Francone, M; Galea, N; Gianfrilli, D; Giannetta, E; Isidori, AM; Lenzi, A; Minnetti, M; Pasqualetti, P; Pofi, R; Pozzilli, P; Sesti, F; Venneri, MA; Vizza, CD | 1 |
| Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L | 1 |
| Bayar, G; Salman, MY; Yavuz, A; Yıldırım, Ç | 1 |
| Aluri, HS; Koka, S; Kukreja, RC; Lesnefsky, EJ; Xi, L | 1 |
| Angulo, J; Cardoso, J; Cuevas, P; Fernández, A; La Fuente, JM; Martínez-Salamanca, JI; Wright, HM | 1 |
| Fogelstrand, P; Jansson, PA; Mattsson Hultén, L; Mobini, R; Olausson, J; Sjögren, L; Strindberg, L | 1 |
| Chopp, M; Jia, L; Lu, M; Lu, X; Szalad, A; Wang, L; Zhang, RL; Zhang, ZG | 1 |
| Jansson, PA; Lönnroth, P; Murdolo, G; Nyström, B; Sjögren, L; Sjöstrand, M; Strindberg, L | 1 |
| Koka, S; Kukreja, RC; Xi, L | 1 |
| Jansson, PA; Lönnroth, P; Murdolo, G; Sjöstrand, M; Strindberg, L | 1 |
| Asadolahzade, A; Esmaeili, S; Farzan, A; Hamidi Madani, A; Mokhtari, G; Shahrokhi Damavand, R | 1 |
| Das, A; Koka, S; Kukreja, RC; Salloum, FN | 1 |
| Anglin, G; Emmick, JT; Knight, JR; Sáenz de Tejada, I | 1 |
| Calogero, AE; Cannizzaro, MA; Condorelli, R; La Vignera, S; Noto, Z; Vicari, E | 1 |
| Brock, GB; Buvat, J; Gambla, M; Hatzichristou, D; Liang, S; Lording, D; Rose, L; Rubio-Aurioles, E; Spera, G | 1 |
1 review(s) available for tadalafil and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hydroxychloroquine; Hyperglycemia; Insulin Resistance; Male; Mice; Myocardial Infarction; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2023 |
8 trial(s) available for tadalafil and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial.
Topics: Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Mellitus, Type 2; Double-Blind Method; Erectile Dysfunction; Female; Humans; Kinetics; Male; MicroRNAs; Penile Erection; Phosphodiesterase 5 Inhibitors; Tadalafil; Treatment Outcome; Ventricular Remodeling | 2022 |
Comparison of three different tadalafil regimens for erectile dysfunction treatment in patients with diabetes mellitus microvascular complications.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Erectile Dysfunction; Humans; Male; Reproducibility of Results; Tadalafil; Treatment Outcome | 2022 |
Postprandial effects of the phosphodiesterase-5 inhibitor tadalafil in people with well-controlled Type 2 diabetes mellitus: a randomized controlled trial.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Endothelial Cells; Female; Forearm; Humans; Insulin Resistance; Male; Meals; Middle Aged; Phosphodiesterase 5 Inhibitors; Postprandial Period; Regional Blood Flow; Tadalafil; Treatment Outcome | 2016 |
The selective phosphodiesterase-5 inhibitor tadalafil induces microvascular and metabolic effects in type 2 diabetic postmenopausal females.
Topics: Adipose Tissue; Body Composition; Carbolines; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Microdialysis; Microvessels; Middle Aged; Muscle, Skeletal; Neovascularization, Pathologic; Phosphodiesterase 5 Inhibitors; Postmenopause; Substrate Specificity; Tadalafil | 2013 |
Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus.
Topics: Adult; Aged; Carbolines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Folic Acid; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Tadalafil; Vitamin B Complex | 2013 |
Effects of tadalafil on erectile dysfunction in men with diabetes.
Topics: Antihypertensive Agents; Carbolines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Glycated Hemoglobin; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Placebos; Tadalafil; Treatment Outcome | 2002 |
Tadalafil and modifications in peak systolic velocity (Doppler spectrum dynamic analysis) in the cavernosal arteries of patients with type 2 diabetes after continuous tadalafil treatment.
Topics: Aged; Alprostadil; Arteries; Attitude to Health; Blood Flow Velocity; Carbolines; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Erectile Dysfunction; Humans; Injections; Luteinizing Hormone; Male; Middle Aged; Nitric Oxide; Penis; Prolactin; Surveys and Questionnaires; Tadalafil; Testosterone; Treatment Outcome; Vasodilator Agents | 2006 |
Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction.
Topics: Adult; Aged; Carbolines; Coitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Erectile Dysfunction; Humans; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors; Severity of Illness Index; Tadalafil; Treatment Outcome | 2008 |
7 other study(ies) available for tadalafil and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Phosphodiesterase 5 inhibitor suppresses prostate weight increase in type 2 diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin-Like Growth Factor I; Male; Phosphodiesterase 5 Inhibitors; Prostate; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Tadalafil; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Weight Gain | 2022 |
Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling.
Topics: Animals; Carbolines; Diabetes Mellitus, Type 2; Heart; Mice; Mitochondria; Myocardium; Nitric Oxide; Oxidative Phosphorylation; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphodiesterase 5 Inhibitors; Signal Transduction; Sirtuin 1; Tadalafil; Transcription Factors | 2014 |
Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Topics: Arteries; Benzopyrans; Carbolines; Cyclic GMP; Diabetes Mellitus, Type 2; Drug Synergism; Erectile Dysfunction; Ethanolamines; Humans; Imidazoles; Male; Middle Aged; Muscle Relaxation; Muscle, Smooth, Vascular; Nebivolol; Nitric Oxide; Penile Erection; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2014 |
Tadalafil Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Models, Animal; Gene Expression Regulation; Humans; Lymphokines; Mice; Mice, Inbred NOD; Motor Activity; Nerve Fibers; Nerve Growth Factor; Peripheral Nervous System Diseases; Platelet-Derived Growth Factor; Sciatic Nerve; Tadalafil | 2016 |
Tadalafil increases muscle capillary recruitment and forearm glucose uptake in women with type 2 diabetes.
Topics: Aged; Area Under Curve; Capillaries; Carbolines; Diabetes Mellitus, Type 2; Female; Forearm; Glucose; Humans; Linear Models; Microdialysis; Middle Aged; Phosphodiesterase Inhibitors; Regional Blood Flow; Tadalafil | 2010 |
Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts.
Topics: Animals; Blotting, Western; Carbolines; Cytoskeleton; Diabetes Mellitus, Type 2; Electrophoresis, Gel, Two-Dimensional; Heart; Male; Mice; Mice, Inbred C57BL; Myocardium; Oxidation-Reduction; Phosphodiesterase 5 Inhibitors; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tadalafil; Ventricular Function, Left | 2012 |
Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice.
Topics: Animals; Apoptosis; Carbolines; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Mice; Mitochondria, Heart; Myocardial Reperfusion Injury; Myocytes, Cardiac; Nitric Oxide; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Reactive Oxygen Species; Tadalafil | 2013 |